StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)

Close on Nov 17, 2026Market cap $253.10MP/E –Yield –

Enanta Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Enanta Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$42.56M. For fiscal 2026 it was -$42.56M. The highest annual figure on record is $76.67M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Sep 30, 2026-$42.56M–
FY2025Sep 30, 2025-$19.27M–
FY2024Sep 30, 2024-$78.76M–
FY2023Sep 30, 2023-$103.15M–
FY2022Sep 30, 2022-$84.78M–
FY2021Sep 30, 2021-$70.00M-1087.5%
FY2020Sep 30, 2020$7.09M-90.1%
FY2019Sep 30, 2019$71.42M+144.4%
FY2018Sep 30, 2018$29.22M-44.5%
FY2017Sep 30, 2017$52.65M+47.0%
FY2016Sep 30, 2016$35.81M-53.3%
FY2015Sep 30, 2015$76.67M+280.0%
FY2014Sep 30, 2014$20.18M+89.4%
FY2013Sep 30, 2013$10.65M-52.9%
FY2012Sep 30, 2012$22.62M-5.8%
FY2011Sep 30, 2011$24.02M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ3 2026Sep 30, 2026-$13.73M–
Q3 FY2026CQ2 2026Jun 30, 2026-$9.97M–
Q2 FY2026CQ1 2026Mar 31, 2026-$7.16M–
Q1 FY2026CQ4 2025Dec 31, 2025-$11.70M–
Q4 FY2025CQ3 2025Sep 30, 2025-$6.49M–
Q1 FY2025CQ4 2024Dec 31, 2024-$16.80M–
Q4 FY2024CQ3 2024Sep 30, 2024-$10.40M–
Q3 FY2024CQ2 2024Jun 30, 2024-$14.78M–
Q2 FY2024CQ1 2024Mar 31, 2024-$28.60M–
Q1 FY2024CQ4 2023Dec 31, 2023-$24.99M–
Q4 FY2023CQ3 2023Sep 30, 2023-$21.60M–
Q3 FY2023CQ2 2023Jun 30, 2023-$32.13M–
Q2 FY2023CQ1 2023Mar 31, 2023-$13.78M–
Q1 FY2023CQ4 2022Dec 31, 2022-$35.64M–
Q4 FY2022CQ3 2022Sep 30, 2022-$15.53M–
Q3 FY2022CQ2 2022Jun 30, 2022-$29.60M–
Q2 FY2022CQ1 2022Mar 31, 2022-$26.38M–
Q1 FY2022CQ4 2021Dec 31, 2021-$13.27M–
Q4 FY2021CQ3 2021Sep 30, 2021-$21.02M–
Q3 FY2021CQ2 2021Jun 30, 2021-$29.51M–
Q2 FY2021CQ1 2021Mar 31, 2021-$4.58M-131.2%
Q1 FY2021CQ4 2020Dec 31, 2020-$14.89M-220.4%
Q4 FY2020CQ3 2020Sep 30, 2020-$15.46M-280.9%
Q3 FY2020CQ2 2020Jun 30, 2020-$4.49M-277.2%
Q2 FY2020CQ1 2020Mar 31, 2020$14.67M-51.2%
Q1 FY2020CQ4 2019Dec 31, 2019$12.36M-59.1%
Q4 FY2019CQ3 2019Sep 30, 2019$8.55M-69.8%
Q3 FY2019CQ2 2019Jun 30, 2019$2.53M-37.4%
Q2 FY2019CQ1 2019Mar 31, 2019$30.09M–
Q1 FY2019CQ4 2018Dec 31, 2018$30.25M+586.2%
Q4 FY2018CQ3 2018Sep 30, 2018$28.34M-50.5%
Q3 FY2018CQ2 2018Jun 30, 2018$4.05M–
Q2 FY2018CQ1 2018Mar 31, 2018-$7.58M–
Q1 FY2018CQ4 2017Dec 31, 2017$4.41M+40.2%
Q4 FY2017CQ3 2017Sep 30, 2017$57.31M–
Q3 FY2017CQ2 2017Jun 30, 2017-$4.80M–
Q2 FY2017CQ1 2017Mar 31, 2017-$3.00M–
Q1 FY2017CQ4 2016Dec 31, 2016$3.15M–
Q4 FY2016CQ3 2016Sep 30, 2016-$2.13M–

More Enanta Pharmaceuticals figures

See a number that looks wrong?